Skeletal metastases from breast and prostate cancer are the cause of significant morbidity and mortality. Mechanisms by which skeletal metastases are established are unclear. Drugs that inhibit osteoclast (OC) function (namely bisphosphonates) ameliorate both osteolytic and osteoblastic metastatic bone disease, suggesting that OCs are involved in the pathogenesis of both forms of bone metastases. One approach to examine the role of OCs in skeletal metastases is the use of a mouse lacking the integrin subunit beta3. We have preliminary data that osteolytic bone metastases are significantly decreased in beta3-/- mice. The beta3-/- mouse has two fundamental defects: diminished osteoclast resorption mediated by alpha-v beta3 and diminished platelet aggregation mediated by alphaIIbeta3, both of which may play a role in the establishment of bone metastases. Blockade of platelet/tumor interactions via the beta3 integrin decreases lung metastases in mice, suggesting a role for platelet beta3 integrin in metastases. Given the above facts, we hypothesize that 1) decreased osteolytic metastases in the beta3-/- mouse arise from diminished OC and/or platelet function; 2) osteoblastic bone metastases will be decreased in the beta3-/- mice as a result of osteoclast and platelet dysfunction. Thus our specific aims are: 1) Determine the roles of defective osteoclasts and defective platelets in inhibiting osteolytic bone metastases. 2) Determine the roles of defective osteoclasts and defective platelets upon the development of osteoblastic bone metastases. Bone metastases will be established in beta3-/- mice and the osteoclast defective src-/- mice and the platelet defective DiYF mice by left cardiac ventricle (LV) and intra-tibial (IT) injection of osteolytic and osteoblastic cells lines. Bone metastases will be monitored by x-ray, 18-fluorodeexyglucose (18-FDG) PET scanning of in vivo tumor activity, and histomorphometry. Inhibitors of osteoclast alpha v beta3 and alphaIIbeta3 platelet specific inhibitors will be used in the osteolytic and osteoblastic LV and IT, bone metastasis assays. These studies will define whether beta3 function on host osteoclasts and platelets facilitate osteolytic and osteoblastic metastases and whether therapeutic inhibition of OC and/or beta3 function has a role in preventing or ameliorating skeletal metastases. These findings will direct future studies to define the molecular role of beta3 integrin subunit in the development of skeletal metastases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA097250-03
Application #
6770118
Study Section
Oral Biology and Medicine Subcommittee 1 (OBM)
Program Officer
Mohla, Suresh
Project Start
2003-07-01
Project End
2008-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
3
Fiscal Year
2004
Total Cost
$340,425
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Murali, Bhavna; Ren, Qihao; Luo, Xianmin et al. (2018) Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss. Cancer Res 78:5618-5630
Ross, Michael H; Esser, Alison K; Fox, Gregory C et al. (2017) Bone-Induced Expression of Integrin ?3 Enables Targeted Nanotherapy of Breast Cancer Metastases. Cancer Res 77:6299-6312
Fontana, Francesca; Ge, Xia; Su, Xinming et al. (2017) Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma. Clin Cancer Res 23:416-429
Su, Xinming; Esser, Alison K; Amend, Sarah R et al. (2016) Antagonizing Integrin ?3 Increases Immunosuppression in Cancer. Cancer Res 76:3484-95
D'Amico, Lucia; Mahajan, Sahil; Capietto, Aude-Hélène et al. (2016) Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. J Exp Med 213:827-40
Luo, Xianmin; Fu, Yujie; Loza, Andrew J et al. (2016) Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development. Cell Rep 14:82-92
Esser, Alison K; Schmieder, Anne H; Ross, Michael H et al. (2016) Dual-therapy with ?v?3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model. Nanomedicine 12:201-11
Ellison, Tim S; Atkinson, Samuel J; Steri, Veronica et al. (2015) Suppression of ?3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis. Dis Model Mech 8:1105-19
Sanfilippo, K M; Gage, B; Luo, S et al. (2015) Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. Leuk Lymphoma 56:615-21
Junankar, Simon; Shay, Gemma; Jurczyluk, Julie et al. (2015) Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov 5:35-42

Showing the most recent 10 out of 36 publications